Selected Grants
CISA 2023 Clinical Contributing Task 1
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028CISA 2023 Clinical Contributing Task 2
ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2027A Phase 3 Study to Evaluate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults
Clinical TrialPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2023 - 2026AIC316-03II-01 A randomized, open-label, multi-center, comparative trial, to assess the efficacy and safety of pritelivir versus foscarnet for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised subjects (PRIOH-1)
Clinical TrialPrincipal Investigator · Awarded by AiCuris Anti-infective Cures AG · 2024 - 2026Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
ResearchPrincipal Investigator · Awarded by Vanderbilt University Medical Center · 2022 - 2025DAS181-3-01
Clinical TrialPrincipal Investigator · Awarded by Ansun BioPharma, Inc · 2019 - 2025SUPERNOVA A Phase 1/3 randomized double blind study to evaluate the safety and neutralizing activity of AZD5156 for pre-exposure prophylaxis of COVID-19 in participants with conditions causing immune impairment
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2023 - 2025Collaboratory of AIDS Researchers for Eradication (CARE)
ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2021 - 2025CISA 07 Adult RCT COVID-19 Vaccination (Lead)
ResearchSafety Coordinator · Awarded by Centers for Disease Control and Prevention · 2020 - 2024Transplant Infectious Diseases Interdisciplinary Research Training Grant (TIDIRTG)
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2018 - 2024ACTG-STOMP A5418
Clinical TrialPrincipal Investigator · Awarded by University of California - Los Angeles · 2022 - 2023CISA Consult 2022 Contributing Task 3
Clinical TrialInvestigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023ACTIV1: Master Protocol for Immune Modulars: Remdisivir in COVID 19 patients
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2020 - 2022CARE Focus 1: Latency Biomarker Project
ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2018 - 2022Ph IIa, randomized, double blind placebo controlled trial of EIDD-2801 to eliminate COVID Viral RNA detection
Clinical TrialPrincipal Investigator · Awarded by Ridgeback Biotherapeutics LP · 2020 - 2022Adaptive COVID-19 Treatment Trial (ACTT)
ResearchPrincipal Investigator · Awarded by Leidos Biomedical Research, Inc. · 2020 - 2021CMV Quant Assay
Clinical TrialPrincipal Investigator · Awarded by Hologic, Inc. · 2019 - 2021Phase III, Remdesivir (GS-5734) in severe COVID-19 participants
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2021Phase III study of Remdesivir in Moderate COVID-19 patients
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2021CARE Duke-UNC Latency Biomarker Supplement Year 2
ResearchInvestigator · Awarded by University of North Carolina - Chapel Hill · 2016 - 2018Insight Flu Studies, M59-DU-074-1101-3 Task Order 4
ResearchInvestigator · Awarded by Institute for Clinical Research, Inc. · 2014 - 2018Duke Continuing Medical Educational Program: CHEST
ConferencePrincipal Investigator · Awarded by American College of Chest Physicians · 2018 - 2018CRB-SSS-S-16-004809 - Protocol IRC 003- TO#Q7
Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2015 - 2017A Phase II Randomized Double-blind Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS-181-2-05)
Clinical TrialPrincipal Investigator · Awarded by Ansun BioPharma,Inc · 2014 - 2017An Open Label study to examine the effects of DAS 181 administered by Dry Powder Inhaler (DPI) or Nebulized formulation in Immunocompromised subjects with Parainfluenza (PIV) Infection
Clinical TrialPrincipal Investigator · Awarded by Ansun BioPharma,Inc · 2013 - 2016Task Order CRB-SSS-S-13-003314 - Protocol IRC 003
Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2013 - 2015Task Order CRB-SSS-S-13-003283 - Protocol IRC004
Clinical TrialPrincipal Investigator · Awarded by Social & Scientific Systems, Inc. · 2013 - 2014External Relationships
- Atea Pharmaceuticals
- Biogen
- CSL Behring
- Jansen Pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.